Category Archives: FOL-005

A Truly Outstanding Week in Hair

As if my last post on Dr. Terskikh’s progress and new company was not enough, three other new developments occurred last week that were extremely encouraging.

Follicum Positive Phase IIa Results

“The clear effect we saw in the growth phase supports the hypothesis that FOL-005 can “awaken” dormant hair follicles.”

I have mentioned Sweden-based Follicum numerous times in the past (see all Follicum past posts). Of the 50 plus companies that I have covered on this blog in the past five years, Follicum has been the most professional in my opinion.

This week, the company announced Phase IIa trial results.

Also, CEO Jan Alenfall gave a much more detailed interview discussing these results.

The quote that I posted above in red is the best part of these results. So now we have yet more evidence that long-lost miniaturized “dead” hair can be reawakened.

There are some issues regarding appropriate dosage levels. Follicum plans to test higher dosages in the next phase of trials. In these Phase IIa results, the highest dose resulted in an 11% median increase in the number of hair follicles in growth phase.

Maintenance of existing hair and an 11% increase in new hair would be amazing considering that this FOL-005 product did not cause any side effects (all too common with Finasteride and Dutasteride). Here’s to hoping for even better results with higher doses.

Samumed Initates Phase 3 Trials

In its latest monthly newsletter, Samumed announced that they have commences Phase 3 clinical trials:

Samumed Phase 3 Trials

Not a big surprise considering my August 2018 post on Samumed’s pending Phase 3 trials. Wonder in which country they are holding these trials?

Dr. Takashi Tsuji Still Aiming for 2020

Thanks to “Winston” for finding this Japanese government website link update on Dr. Takashi Tsuji’s work. Dr. Tsuji is partnering with Kyocera, RIKEN and Organ Technologies, so those companies also need to be mentioned. Key quote:

“Regenerating hair follicles is the beginning of that road, and after preclinical and safety testing, our goal is to implement it by 2020. Starting by curing baldness, our intention is to develop an industry aimed at improving quality of life.”

I would want nothing more than an end to baldness and a cessation of my writing these posts after December 31st, 2020. Dr. Tsuji is my number 1 hope of making this happen. He has the requisite intelligence, ethics, drive, decades of research experience, corporate funding and government support.

Addendum: A few people posted comments or e-mailed me about new UK-based hair regeneration company btechlaboratories (since Fuji Maru from Japan covered this company recently). However, btechlabs currently has an insecure (non-https://) website with bad quality writing and layout. And their Twitter link goes to a host provider’s Twitter account. I would expect my readers to be a bit less gullible.


Follicum Develops Direct-to-Scalp Formulation of FOL-005

Follicum FOL-005

I have covered Swedish company Follicum numerous times on this blog in the past, including twice earlier this year. The company is developing a topical scalp hair stimulation product called FOL-005 that is based on the human protein osteopontin. Interestingly, a variation of this same drug will likely be developed by Follicum in order to reduce body hair. Definitely read my post on excessive body hair in men and its correlation with scalp hair loss.

Of the numerous companies in the world that are developing a treatment or cure for hair loss, Follicum is currently the most professional when it comes to its communications and its product development strategy. Their clinical trial time-frames for each stage have generally been accurate over the past few years. And they seem to be on schedule to continue to hit targets over the next year.

Follicum Topical Formulation Milestone

Earlier today, I got an e-mail from Follicum notifying me of their achieving a major milestone. The company has now successfully developed a direct-to-scalp topical formulation for their FOL-005 hair stimulation drug. This will in the near future replace their current method of delivery (intradermal injections) of FOL-005.

This new proprietary topical formulation is a non-running gel, making it easy to apply. The formulation remains stable for several years at room temperature storage. Moreover, the formulation is designed to ensure good skin penetration and distribution in both the epidermis and the hair follicles.

According to CEO Jan Alenfall, Follicum’s extensive experience in developing peptide drugs has enabled the company to develop a stable formulation that delivers FOL-005 directly to the hair follicle.

Company Advisory Board

While browsing through Follicum’s website today, I also noticed that their scientific advisory board page seems to have been updated recently. They now have a highly respectable and accomplished group of advisers, many of whom have been covered on this blog in the past. The most well known of these in the hair loss world are Dr. Gerd Lindner (Germany), Dr. Ralf Paus (UK/Germany), Dr Ulrike Blume-Peytavi (Germany) and Dr. Amos Golhar (Israel).

If all continues to go well in Phase II trials, it is not out of the question that Follicum’s hair growth product could be released around the end of 2020. However, this is not going to be a hair loss cure. Just a new hair loss treatment with no major side effects.